Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prostatic hypertrophy treatment claims for saw palmetto draw FDA "courtesy" letters.

This article was originally published in The Tan Sheet

Executive Summary

BPH TREATMENT CLAIMS DRAW FDA "COURTESY" LETTERS for structure/function claims that suggest the dietary supplements are "intended to treat, mitigate, or pre-vent a disease, namely benign prostatic hypertrophy," FDA says. One letter was sent to Celestial Seasonings, which had notified the agency in January it was using the structure/function claims "Helps maintain healthy, comfortable urinary flow and frequency" and "Natural support for men over age 40" for its Celestial Seasonings Saw Palmetto Standardized Herbal Extract. The firm has not decided whether it will change the claims.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel